{
    "clinical_study": {
        "@rank": "75461", 
        "acronym": "RebiQoL", 
        "arm_group": [
            {
                "arm_group_label": "Technical support for the RebiSmart\u2122 device", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Patient support program (MinSupport Plus)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, comparative, and multicenter study to assess the impact of a patient\n      support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in\n      subjects with relapsing-remitting multiple sclerosis administered Rebif\u00ae with the RebiSmart\u2122\n      device."
        }, 
        "brief_title": "A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif\u00ae With the RebiSmart\u2122 Device", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multiple Sclerosis", 
            "Relapsing-Remitting"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged 18 or older\n\n          -  A diagnosis of relapsing-remitting multiple sclerosis according to the revised\n             McDonald Criteria (2010)\n\n          -  Treatment with Rebif\u00ae 22 or 44 mcg subcutaneously three times a week in accordance to\n             the Summary of product characteristics\n\n          -  Rebif\u00ae administered by the RebiSmart\u2122 device\n\n          -  Provided a signed informed consent form\n\n        Exclusion Criteria:\n\n          -  Has received any components, except for technical support, of MinSupport Plus prior\n             to study entry\n\n          -  Has difficulty reading and/or understanding Swedish\n\n          -  Has a mental condition rendering the subject unable to understand the nature, scope\n             and possible consequences of the study, and/or evidence of an uncooperative attitude\n\n          -  No access to computer\n\n          -  Participation in another clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791244", 
            "org_study_id": "EMR 200136-560", 
            "secondary_id": "2012-004887-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "Technical support for the RebiSmart\u2122 device", 
                "description": "Rebif\u00ae will be administered by the RebiSmart\u2122 device at a dose of either 22 or 44 microgram (mcg) three times a week in accordance to the summary of product characteristics. Subjects will receive only technical support for the RebiSmart\u2122 device.", 
                "intervention_name": "Technical support for the RebiSmart\u2122 device", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Patient support program (MinSupport Plus)", 
                "description": "Rebif\u00ae will be administered by the RebiSmart\u2122 device at a dose of either 22 or 44 microgram (mcg) three times a week in accordance to the summary of product characteristics. Subjects will receive support program (MinSupport Plus) which includes technical support for RebiSmart\u2122 device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.", 
                "intervention_name": "Patient support program (MinSupport Plus)", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interferon beta 1a"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Multiple Sclerosis", 
            "Relapsing-Remitting", 
            "Rebif", 
            "RebiSmart", 
            "Patient support program"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "service@merckgroup.com", 
                    "last_name": "Merck Communication Services", 
                    "phone": "+49-6151-75-5200"
                }, 
                "facility": {
                    "address": {
                        "city": "Darmstadt", 
                        "country": "Germany"
                    }, 
                    "name": "Please contact the Merck Communications Service for Recruiting locations"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "G\u00e4vle", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karlstad", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "KS Huddinge", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malm\u00f6/Lund", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sk\u00f6vde", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u00d6rnsk\u00f6ldsvik", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif\u00ae With the RebiSmart Device", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) psychological score at Month 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791244"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) psychological score at Month 6", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Month 6"
            }, 
            {
                "measure": "Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) total score at Month 6 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6 and 12"
            }, 
            {
                "measure": "Change from Baseline in Euro Quality of Life Questionnaire with 5 questions alternatives (EQ5D-5L) score at Month 6 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6 and 12"
            }, 
            {
                "measure": "Percentage of subjects with treatment adherence", 
                "safety_issue": "No", 
                "time_frame": "Month 6 and 12"
            }, 
            {
                "measure": "Change from Baseline in Fatigue Severity Scale score and Modified Fatigue Impact Scale score at Month 6 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6 and 12"
            }, 
            {
                "measure": "Change from Baseline in Hospital Anxiety and Depression Scale score at Month 6 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6 and 12"
            }, 
            {
                "measure": "Change from Baseline in Working ability per subject at Month 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Month 12"
            }, 
            {
                "measure": "Percentage of subjects with Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Month 12"
            }, 
            {
                "measure": "Number of subjects with categorical score on subject satisfaction questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Month 12"
            }, 
            {
                "measure": "Number of health care personnel with categorical score on Health Care Personnel satisfaction questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Month 12"
            }, 
            {
                "measure": "Change from Baseline in Lifestyle questionnaire score in subjects receiving Min Support Plus at Month 6 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6 and 12"
            }, 
            {
                "measure": "Number of subjects with Lifestyle goals score in subjects receiving Min Support Plus", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Month 12"
            }, 
            {
                "measure": "Health economy as assessed by Quality of life questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Month 12"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}